MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-26-2026
Orgenesis Cash and Cash Equivalents 2011-2026 | ORGS
Annual Cash and Cash Equivalents Orgenesis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 78 K | 837 K | 5.31 M | 5.47 M | 44.9 M | - | 16.5 M | 3.52 M | 891 K | 4.17 M | 1.31 M | 50.8 K | 347 | 1.28 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.9 M | 347 | 6.39 M |
Quarterly Cash and Cash Equivalents Orgenesis
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 204 K | 77 K | 80 K | 837 K | 55 K | 180 K | 2.67 M | 5.31 M | 3.02 M | 2.3 M | 1.12 M | 5.47 M | 14.9 M | 28.4 M | 41.8 M | 44.9 M | 44.9 M | 44.9 M | 44.9 M | 107 K | 107 K | 107 K | 107 K | 15 M | 17.1 M | 15 M | 15 M | 3.52 M | 3.52 M | 3.52 M | 3.52 M | 891 K | 891 K | 891 K | 891 K | 4.17 M | 4.17 K | 4.17 K | 4.17 K | 1.31 M | 1.31 M | 1.31 M | 1.31 M | 51 K | 50.8 K | 50.8 K | 50.8 K | 347 | 347 | 347 | 347 | 1.28 K | 1.28 K | 1.28 K | 1.28 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 44.9 M | 347 | 6.84 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
1.66 B | $ 330.34 | 3.6 % | $ 43.3 B |  USA |
 |
BioLineRx Ltd.
BLRX
|
10.4 M | $ 2.25 | 1.81 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
103 M | $ 2.96 | -1.0 % | $ 252 M | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 91.28 | 0.11 % | $ 27.2 B | Germany |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
3.22 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aquestive Therapeutics
AQST
|
121 M | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
231 M | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
28.9 M | $ 31.37 | 1.0 % | $ 2.08 B | USA |
 |
Avenue Therapeutics
ATXI
|
2.86 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
Axcella Health
AXLA
|
17.1 M | - | -16.42 % | $ 249 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
42.9 M | $ 23.66 | 0.11 % | $ 3.01 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
222 M | - | - | $ 546 M | USA |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
10.9 M | - | -5.38 % | $ 6.06 M | USA |
 |
Ardelyx
ARDX
|
68 M | $ 5.97 | 0.51 % | $ 1.44 B | USA |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
CASI Pharmaceuticals
CASI
|
38.7 M | - | - | $ 35.4 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | USA |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
argenx SE
ARGX
|
3.49 B | $ 748.25 | 0.25 % | $ 25 B |  Niderland |